Analysis on point mutation of the CDKN2/p16 gene in lung cancer.
- Author:
Changqing SU
1
;
Yukun YE
;
Dong WANG
;
Xiangrong CAO
;
Shufeng LI
;
Xiangnian SHAN
Author Information
- Publication Type:Journal Article
- MeSH: Cyclin-Dependent Kinase Inhibitor p16; genetics; Exons; Humans; Lung Neoplasms; genetics; Point Mutation; Polymerase Chain Reaction; methods; Polymorphism, Single-Stranded Conformational; Sequence Analysis, DNA; methods
- From: Chinese Journal of Medical Genetics 2002;19(1):37-40
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the status of CDKN2/p16 gene point mutation in lung cancer.
METHODSPolymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and sequencing were used to detect the point mutation of CDKN2/p16 gene exon 2 in 89 cases of lung cancer.
RESULTSIn 69 cases of the lung cancer without deletion of CDKN2/p16 gene exon 2, 16 cases were found to have suspicious abnormality of CDKN2/p16 gene exon 2 by PCR-SSCP, and in these 16 cases, 9 were found to harbor point mutations of CDKN2/p16 gene exon 2 by automated sequencing analysis.
CONCLUSIONThe point mutation is one of the mechanisms for CDKN2/p16 gene inactivation, but it is not the chief mechanism. The inactivation of CDKN2/p16 gene aroused by point mutation plays a role to some extent in the genesis and progression of lung cancer.
